Home > Oncology > ELCC 2019 > Immunotherapy in Stage 4 Lung Cancer > Other I-O combinations

Other I-O combinations

Presented By
Prof. Solange Peters, Lausanne University Hospital and Ludwig Institute, Switzerland
Conference
ELCC 2019
Trial
IMpower 150
Most combination therapies containing multiple I-O agents being studied in stage 4 lung cancer have anti-PD1/PD-L1 as backbone [1]. Prof. Solange Peters (Lausanne University Hospital and Ludwig Institute, Switzerland) speculated that this might become different in the future. Our current knowledge about the parameters for I-O success has been described in “a wonderful paper which was recently published in Nature Medicine [2]”, Prof. Peters said. “Some intrinsic resistance mechanisms in the tumour are described, which are increasingly being addressed by new compounds.” Furthermore, this knowledge provides a rationale for the evaluation of new I-O/I-O combinations, in which the individual compounds have distinct mechanisms of action. She also addressed the lack of suitable biomarkers for patient selection and monitoring. In the ongoing effort to develop specific biomarkers for ICI therapy, multiple factors should be taken into consideration, ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on